Needham & Company Reiterates a 'Buy' on Lexicon Pharmaceuticals (LXRX); Encouraging Phase 2 LX1032 Results in Sandostatin-Treated Carcinoid Syndrome Patients
Go back to Needham & Company Reiterates a 'Buy' on Lexicon Pharmaceuticals (LXRX); Encouraging Phase 2 LX1032 Results in Sandostatin-Treated Carcinoid Syndrome Patients| Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) | Delayed: 2.32 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.32 | 52 Week High | $19.62 | |||
| Open | $2.32 | 52 Week Low | $7.65 | |||
| Day High | $2.32 | P/E | N/A | |||
| Day Low | $2.32 | EPS | $-0.22 | |||
| Volume | 3,099 | |||||
